Alphatec Holdings, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst David Saxon from Needham reiterated a Buy rating on the stock and has a $22.00 price target.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
David Saxon has given his Buy rating due to a combination of factors tied to Alphatec’s recent performance and forward outlook. He notes that despite the stock pulling back roughly 20% after a strong run, the company just preannounced fourth-quarter 2025 revenue modestly ahead of Wall Street expectations, with both its Surgical and EOS segments exceeding consensus. Saxon also highlights that Surgical volumes accelerated meaningfully in 2025 versus 2024, while management reaffirmed EBITDA and free cash flow guidance and ended the year with a stronger cash position.
Saxon views the initial 2026 revenue guidance as intentionally conservative, pointing out that the implied growth trajectory leaves a relatively low hurdle to reach—and potentially surpass—the company’s $1 billion 2027 revenue goal, where he sees additional upside. He underscores that 2026 expectations for revenue, EBITDA, and free cash flow all support continued operating leverage and margin expansion. Finally, he points to strategic moves such as securing exclusive U.S. distribution rights to Theradaptive’s OsteoAdapt biologic as incremental pipeline and growth optionality, reinforcing his view that the recent share-price weakness represents an attractive entry point for investors.
In another report released yesterday, TD Cowen also reiterated a Buy rating on the stock with a $27.00 price target.